ESSA Pharma Inc

Análisis de la acción ESSA Pharma Inc (EPIX)

$0.201

-0.004 (-1.85%)Al cierre

Loading chart…
High
0.207
Open
0.200
VWAP
0.20
Vol
5.95M
Mkt Cap
229.80M
Low
0.190
Amount
1.19M
EV/EBITDA, TTM
0.00

ESSA Pharma Inc. is a Canada-based pharmaceutical company that was previously focused on developing therapies for the treatment of patients with prostate cancer. The Company is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.

Métricas de valoración

The current forward P/E ratio for ESSA Pharma Inc (EPIX) is -0.33, compared to its 5-year average forward P/E of -4.95.

Forward P/E

Overvalued
5Y Average P/E
-4.95
Current P/E
-0.33
Sobrevalorada
-2.07
Infravalorada
-7.83

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.49
Current EV/EBITDA
0.00
Sobrevalorada
1.51
Infravalorada
-2.49

Forward P/S

Fair
5Y Average P/S
1.01
Current P/S
0.00
Sobrevalorada
7.45
Infravalorada
-5.43

Alphio AI Price Scenarios for EPIX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EPIX

$2.26

Precio del escenario

B

Base

Base · 50%EPIX

$2.05

Precio del escenario

B

Bear

Bear · 25%EPIX

$1.89

Precio del escenario

Whales holding EPIX

B

BVF Partners L.P.

+ HoldingEPIX

+16.11%

3M Return

Cronología de eventos

2025-10-06 (ET)

17:16:17

Essa Pharma Shareholders Greenlight XenoTherapeutics Acquisition

2025-09-30 (ET)

16:35:37

Essa Pharma shares update on partnership agreement with Xeno

2025-09-24 (ET)

07:02:34

Essa Pharma modifies its business combination agreement with XenoTherapeutics.

2025-07-14 (ET)

08:03:59

XenoTherapeutics to acquire Essa Pharma

2025-02-11 (ET)

06:08:22

Essa Pharma reports Q4 EPS (19c) vs. (14c) last year

Noticias

EPIX FAQ — answered by Alphio AI

ESSA Pharma Inc. is a Canada-based pharmaceutical company that was previously focused on developing therapies for the treatment of patients with prostate cancer. The Company is undergoing a comprehensive review process to review its strategic options to maximize shareholder value. It operates in the Financials sector (PHARMACEUTICAL PREPARATIONS industry).

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis